Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia

Meropenem is commonly used in the ICU to treat gram-negative infections. Due to various pathophysiological changes, critically ill patients are at higher risk of having subtherapeutic concentrations and hence have a higher risk of treatment failure—especially in regions where gram-negative drug resi...

Full description

Saved in:
Bibliographic Details
Published in:Saudi pharmaceutical journal 2021-11, Vol.29 (11), p.1272-1277
Main Authors: Alsultan, Abdullah, Dasuqi, Shereen A., Aljamaan, Fadi, Omran, Rasha A., Syed, Saeed Ali, AlJaloud, Turki, AlAhmadi, Abdullah, Alqahtani, Saeed, Hamad, Mohammed A.
Format: Article
Language:English
Subjects:
ICU
Meropenem
Original
Pharmacokinetics
Saudi Arabia
Sepsis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Meropenem is commonly used in the ICU to treat gram-negative infections. Due to various pathophysiological changes, critically ill patients are at higher risk of having subtherapeutic concentrations and hence have a higher risk of treatment failure—especially in regions where gram-negative drug resistance is increasing, such as Saudi Arabia. No studies have evaluated the pharmacokinetics of meropenem in critically ill patients in Saudi Arabia. Our primary objective is to assess the percentage of patients achieving the therapeutic target for meropenem. This prospective observational study was conducted in the ICUs of King Khalid University Hospital. Patient were included if >18 years-of-age and received meropenem for a clinically suspected or proven bacterial infection. The primary outcome was to assess the percentage of patients who achieved the pharmacokinetic/pharmacodynamic (PKPD) therapeutic target of a free trough concentration four times the MIC. The secondary outcome was to estimate the pharmacokinetics of meropenem. Pharmacokinetic analysis was performed using Monolix Suite 2020R1 (Lixoft, France). Trough concentrations were highly variable and ranged from
ISSN:1319-0164
2213-7475
DOI:10.1016/j.jsps.2021.09.017